drugset / Trial / NCT00871403
Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to determine whether the combination of pazopanib and pemetrexed is safe and effective in the treatment of advanced non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2009-07
- Primary completion
- 2011-03
- Completion
- 2011-03
Outcome
Missed primary endpoint
registry analysis (superiority or other test); Pazopanib 800 mg Plus Pemetrexed 500 mg/m^2 vs Cisplatin 75 mg/m^2 Plus Pemetrexed 500 mg/m^2; p = 0.2647 NCT00871403 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |